The same study also showed increased risk of progression to hip and knee OA in patients with diabetes, with or without obesity, who were exposed to GLP-1 agonists compared to patients with diabetes, with or without obesity, who were not exposed to GLP-1 agonists.58 This evidence concerns the gene GCG and obesity disorder.